Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Abeona Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Abeona Therapeutics announced earnings per share of $-1.4800 on revenue of $0.00. Analysts polled by Investing.com EPS of $-1.4700 on revenue of $0.
Abeona Therapeutics 's are down 45% and is trading at $4.0082 , still down 82.98% from its 52 week high of $23.55 set on Monday, November 15, 2021.
Abeona Therapeutics shares lost 8.70% to trade at $4.0082 in intra-day trade the report.
Abeona Therapeutics follows other major Healthcare sector earnings this month
Abeona Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar